TULIKIVI CORPORATION STOCK EXCHANGE RELEASE 25 MARCH 2026 AT 1:00 P.M. EET Notice is given to the shareholders of Tulikivi Corporation to the Annual General Meeting to be held on Thursday 22 April 2026 starting at 12:00 p.m. at the premises of Borenius Attorneys Ltd, Eteläesplanadi 2, 00130 Helsinki. The reception of persons who have registered for the meeting will commence at 11:30 a.m. A. Matters on the agenda of the general meeting The following matters will be considered at the Annual General Meeting: 1 ...

Core Viewpoint - Merck has announced its acquisition of Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which represents a premium of 31% over the 60-day average stock price and 42% over the 90-day average stock price as of March 24, 2026 [2][3]. Company Overview - Merck, known as MSD outside the U.S. and Canada, is enhancing its oncology portfolio through the acquisition of Terns, which focuses on developing innovative therapies for chronic myeloid leukemia (CML) [2][3]. - Terns Pharmaceuticals is a clinical-stage oncology company with a lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor [2][4]. Acquisition Details - The acquisition is subject to Terns' stockholders tendering their shares and regulatory approvals, with an expected closing in the second quarter of 2026 [5]. - The transaction will be accounted for as an asset acquisition, resulting in a charge of approximately $5.8 billion, or about $2.35 per share, impacting both second quarter and full year 2026 financial results [5]. Product Development - TERN-701 is currently in Phase 1/2 development, specifically in the CARDINAL trial for patients with Philadelphia chromosome-positive CML who have experienced treatment failure or intolerance [3][11]. - The FDA granted Orphan Drug Designation for TERN-701 in March 2024, indicating its potential significance in treating CML [3]. Clinical Trial Insights - Early clinical trials of TERN-701 have shown promising results, including encouraging rates of major molecular response and low incidence of severe adverse events [4][11]. - The CARDINAL trial has completed its dose escalation phase with no dose-limiting toxicities observed, and the expansion phase is currently underway [11]. Market Need - There remains a significant need for innovative therapies in CML, as existing treatments may not provide optimal responses for all patients [5][12]. - TERN-701 aims to offer a differentiated option for patients, potentially improving efficacy and safety compared to current treatments [5][10].

Core Viewpoint - Falcon Oil & Gas Ltd. is providing an update on its transaction with Tamboran Resources Corporation, which is still pending final court approval and other conditions for completion [2][3]. Transaction Update - The transaction was approved by Falcon's shareholders on 11 March 2026 and is subject to several conditions outlined in the arrangement agreement dated 30 September 2025 [2][3]. - The Supreme Court of British Columbia is expected to hear the case on 26 March 2026, after delays due to court backlogs [3][5]. - Key conditions for the transaction include court approval, authorization for listing on the New York Stock Exchange, absence of prohibitive laws, no material adverse changes to either company, and other standard closing conditions [4][5]. Completion Timeline - Falcon anticipates that the transaction could be completed shortly after the court hearing on 26 March 2026, but there is uncertainty regarding the timely acquisition of the Final Order [5]. - If the transaction is not completed by 30 March 2026, either party may terminate the arrangement agreement [5].

Core Viewpoint - ADMA Biologics, Inc. has responded to a negative report by Culper Research, which holds a short position in the company, asserting that the report is based on speculative and unreliable sources, while ADMA emphasizes its commitment to accurate financial reporting and compliance with regulations [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM for primary immunodeficiency, and NABI-HB for hepatitis B immunity [2]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, and operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida [2]. Group 2: Regulatory Compliance and Response - ADMA's Board of Directors is committed to fair and accurate reporting of its financial results and adheres to U.S. Securities and Exchange Commission regulations and U.S. GAAP standards [1]. - The company is taking steps to review the assertions made in the Short Report, which it claims contains numerous misleading and inaccurate statements [1].

Core Viewpoint - PDD Holdings Inc. is focused on high-quality development and strategic investments in supply chain to drive growth in the coming decade [3][5]. Financial Performance - **Fourth Quarter 2025 Results**: Total revenues reached RMB 123,912.2 million (US$ 17,719.2 million), marking a 12% increase from RMB 110,610.1 million in Q4 2024 [5][7]. - **Operating Profit**: Operating profit for the quarter was RMB 27,719.7 million (US$ 3,963.9 million), up from RMB 25,592.2 million in the same quarter of 2024 [7][10]. - **Net Income**: Net income attributable to ordinary shareholders was RMB 24,541.0 million (US$ 3,509.3 million), a decrease of 11% from RMB 27,446.6 million in Q4 2024 [11][12]. - **Non-GAAP Measures**: Non-GAAP net income attributable to ordinary shareholders was RMB 26,295.4 million (US$ 3,760.2 million), down 12% from RMB 29,850.9 million in Q4 2024 [11][12]. Revenue Breakdown - **Online Marketing Services**: Revenues from online marketing services were RMB 60,010.1 million (US$ 8,581.3 million), a 5% increase from RMB 57,011.1 million in Q4 2024 [8]. - **Transaction Services**: Revenues from transaction services increased by 19% to RMB 63,902.1 million (US$ 9,137.9 million) from RMB 53,599.0 million in Q4 2024 [8]. Annual Financial Overview - **Fiscal Year 2025 Results**: Total revenues for the fiscal year were RMB 431,845.7 million (US$ 61,753.1 million), a 10% increase from RMB 393,836.1 million in 2024 [14]. - **Cost of Revenues**: Total costs of revenues rose by 23% to RMB 188,801.8 million (US$ 26,998.3 million) from RMB 153,900.4 million in 2024 [15]. - **Operating Expenses**: Total operating expenses increased by 13% to RMB 148,419.9 million (US$ 21,223.8 million) from RMB 131,512.9 million in 2024 [15]. Cash Flow and Assets - **Cash Position**: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled RMB 422.3 billion (US$ 60.4 billion), up from RMB 331.6 billion a year earlier [13]. - **Net Cash from Operating Activities**: Net cash generated from operating activities was RMB 24,119.5 million (US$ 3,449.0 million), compared to RMB 29,547.2 million in Q4 2024 [12][21]. Management Commentary - The management emphasized a commitment to long-term investments in supply chain and adapting to the rapidly changing external environment to meet consumer needs [3][6].

Core Insights - Akamai has launched Akamai Brand Guardian, an AI-powered solution designed to identify and manage brand impersonation across various digital platforms, enhancing customer trust and revenue protection [1][2] Group 1: Product Features - Akamai Brand Guardian utilizes AI to provide continuous monitoring and risk-based enforcement, replacing traditional reactive methods with proactive measures [2][3] - The solution boasts a 99.99% accuracy rate in automated takedowns of fraudulent content, significantly improving response times for organizations [2][7] - It integrates brand protection capabilities into broader security workflows, offering organizations a comprehensive view of their digital risks [3][7] Group 2: Industry Context - The rise of generative AI has enabled scammers to create sophisticated fake websites and digital identities rapidly, posing significant threats to sectors like financial services, retail, and healthcare [2] - Companies face challenges in maintaining digital integrity due to the speed at which fraudulent sites are generated, leading to potential revenue loss and damaged customer relationships [2][3] Group 3: Operational Benefits - The solution allows security teams to detect threats automatically, prioritizing high-value risks based on real-time data [7] - Automated workflows facilitate quicker investigations and takedowns of fraudulent sites, aligning response times with the rapid pace of scam operations [7] - By combining brand abuse data with broader security insights, organizations can build a more complete defense against digital threats [7]

Core Insights - Amaze Holdings, Inc. has transitioned from stabilizing its business in 2025 to focusing on scaling opportunities in 2026 [2][11] - The company is implementing a "Creator Commerce Flywheel" to enhance its platform and accelerate growth [3][14] - Data generated across the ecosystem is recognized as a core asset, with plans to leverage it for actionable tools for creators and brands [4][5] Business Strategy - The company aims to expand distribution through partnerships with trusted media brands, exemplified by a collaboration with LA Times Studios [8][9] - The strategy includes integrating commerce into high-intent environments, differentiating from traditional affiliate models [9] - Priorities for 2026 include creator commerce, proprietary data, and distribution infrastructure [12][14] Financial Performance - 2025 was characterized as a year of transition, with necessary actions taken to improve efficiency and strategic direction [11] - Early indicators from the Food Channel initiatives suggest potential gross revenues of multi-million dollars in the first year, scaling to $12 million in the second year [16] - The company is focused on driving operating leverage as it scales, aiming for modular and repeatable revenue growth across various verticals [17]

Core Viewpoint - NOV Inc. plans to invest $200 million to double the capacity of its subsea flexible pipe manufacturing facility in Açu, Brazil, over the next three years to meet anticipated long-term demand in the offshore development sector [1][2][8]. Investment and Capacity Expansion - The investment will increase the company's capital expenditure plan for 2026 by approximately $50 million [4]. - The current manufacturing facility is operating at or near full utilization, with a backlog extending into 2028, indicating a strong demand for subsea flexible pipes [3][4]. Market Demand and Industry Position - The expansion is driven by expected growth in deepwater developments and a replacement cycle for flexible pipe installations, suggesting that current industry capacity will be insufficient to meet future demand [2][3]. - NOV's facility in Açu is strategically designed to accommodate this expansion at a lower cost compared to building a new plant, positioning the company favorably in the market [4][8]. Technological Advancements - The expansion will enable NOV to introduce new technologies, including CO₂-resistant subsea flexible pipes, which could broaden the market for flexible pipe applications [4][8]. - Petrobras, as a key customer, supports this investment, emphasizing the importance of subsea flexible pipes in achieving offshore production targets [4].

Core Viewpoint - The company is actively executing its share repurchase program, demonstrating a strong commitment to shareholder returns and confidence in its long-term growth potential [1][2][4]. Share Repurchase Program - On March 24, 2026, the company utilized approximately RMB34.4 million to repurchase 748,552 ordinary shares, bringing the total share repurchase expenditure for the year to nearly RMB450 million [1]. - The board approved an increase in the total authorization for the share repurchase program to up to US$400 million, which will be effective through August 28, 2027 [2]. Dividend and Share Repurchase Allocation - Starting from 2026, the company will allocate no less than 50% of its adjusted net income from the preceding fiscal year for dividends and share repurchases over the next three years [3]. - The board retains the discretion to adjust the share repurchase and dividend plan based on various factors, including financial performance and market conditions [3]. Management Confidence - These initiatives reflect the management's confidence in the company's long-term growth and commitment to delivering sustainable value to shareholders [4].

Core Viewpoint - Comstock Inc. will participate in the Lytham Partners 2026 Industrials & Basic Materials Investor Summit on April 1, 2026, showcasing its commitment to clean energy systems and resource sustainability [1][2]. Company Overview - Comstock Inc. specializes in innovating and commercializing technologies that support clean energy systems by efficiently extracting and converting under-utilized natural resources into reusable metals, including silver, aluminum, and gold, primarily from end-of-life photovoltaics [3]. Communication Strategy - The company utilizes its investor relations link and main website, along with social media platforms like X.com, LinkedIn, and YouTube, to disclose material non-public information and comply with regulatory obligations [4].